In Vitro Diagnostics Packaging Market Size, Share, Growth Analysis and Industry Trends, 2026–2034

In Vitro Diagnostics Packaging Market Overview: Specimen Integrity, Reagent Stability and Decentralized Testing Define Demand

The global In Vitro Diagnostics Packaging Market is valued at USD 10.0 billion in 2025 and is projected to reach USD 15.2 billion by 2034, expanding at a CAGR of 4.8%. Within the broader healthcare packaging market, IVD packaging encompasses packaging and collection systems used to preserve, organize, identify and transport specimens, reagents, controls, calibrators and diagnostic devices. The segmentation covers reagent and solution bottles, blood collection tubes, sample and transport tubes, vials and ampoules, culture and media bottles, microplates and dishes, pouches and bags, folding cartons and trays, labels and package inserts.

IVD packaging differs from broader medical device packaging because product performance is closely linked to pre-analytical specimen quality and reagent stability. Blood and urine collection systems can incorporate anticoagulants, clot activators or preservatives; liquid reagents require containers that control evaporation and environmental exposure; lateral-flow and molecular tests can require moisture-protective pouches or active materials; and point-of-care kits combine several components in a defined testing sequence. Not all IVD packages are sterile, making contamination control, container integrity, stability and correct identification broader market requirements than sterility alone.

The growth of decentralized diagnostics is also changing packaging architecture. Tests increasingly move between centralized laboratories, physician offices, pharmacies and homes, creating greater demand for compact kits containing collection devices, reagents, droppers, cassettes, lancets, swabs and instructions. Packaging consequently performs both a protective and organizational role by keeping components associated with the correct assay and supporting the intended test workflow.

Current industry development is concentrated around closed specimen-collection systems, specimen-preserving tubes, high-barrier and active packaging, cleanroom-manufactured diagnostic pouches and trays, regulated labeling, UDI and temperature-controlled specimen transport. These developments give the market a more specific technical identity than generic smart-packaging, RFID or sustainability narratives.

Recent Developments and Company Strategies in In Vitro Diagnostics Packaging

BD Introduces Three-Tube Closed Urine Collection System

In February 2026, Becton, Dickinson and Company (BD) launched the BD Vacutainer Urine Complete Cup Kit, a three-tube system designed to enable broader testing from a single urine specimen. The configuration combines a collection cup with integrated transfer functionality, a culture-and-sensitivity tube, a urinalysis tube and a no-additive tube.

The closed-system architecture reduces manual specimen transfers and is designed to limit contamination, leakage and unnecessary specimen handling. BD also states that the system supports automated laboratory workflows. The development demonstrates how IVD packaging can directly influence specimen preservation and pre-analytical workflow rather than functioning only as an outer protective format.

Greiner Bio-One Expands Specimen-Stability Functionality in Urine Collection Tubes

Greiner Bio-One's VACUETTE Urine STB tube incorporates a preservative system designed to stabilize key urinalysis parameters for up to 72 hours at room temperature without refrigeration. The evacuated PET tube uses a spray-dried stabilizer and is available in several volumes and geometries.

Greiner's 2025 technical documentation identifies urine collection, transport and storage as interconnected pre-analytical variables. The platform demonstrates a packaging trend in which the specimen container contributes chemically to sample preservation, potentially changing the allowable time and temperature between collection and analysis.

Oliver Healthcare Packaging Adds 120,000-Square-Foot Asia-Pacific Packaging Capacity

In 2025, Oliver Healthcare Packaging opened its new Johor, Malaysia manufacturing facility, its largest facility in Asia. The 120,000-square-foot site serves diagnostic, pharmaceutical and medical-device applications and incorporates ISO Class 7 and Class 8 cleanroom capability. Production includes medical pouches, converted rollstock and die-cut lidding.

The investment expands regional converting capacity for protective and barrier packaging near Asia-Pacific diagnostic and medical-technology manufacturing clusters.

Nelipak Expands Diagnostic and Healthcare Packaging Capacity in Costa Rica

In July 2025, Nelipak Healthcare Packaging broke ground on a 60,000-square-foot manufacturing facility in Grecia, Costa Rica. The ISO 13485-certified site includes ISO Class 7 cleanroom manufacturing and is designed to serve medical-device, diagnostic and pharmaceutical applications.

Planned capabilities include thin- and heavy-gauge thermoforming, die-cut pouch cards and inserts, together with warehousing for flexible healthcare packaging. The development extends Nelipak's production presence within an established Central American life-sciences manufacturing cluster.

Amcor Develops High-Barrier Recycle-Ready Laminates for Diagnostic Sensors

In February 2025, Amcor introduced Recycle-Ready High Shield Medical Laminates for applications including diagnostic sensors, catheters and wound-care products. The structures use mono-PE-oriented architectures and are available in clear and metallized versions offering different moisture-barrier levels.

The development demonstrates that material simplification is entering selected diagnostic-device packaging applications, although barrier requirements remain application-specific. Amcor itself notes that aluminum remains appropriate for products requiring an absolute barrier, illustrating the continued coexistence of conventional and recycle-ready structures.

In Vitro Diagnostics Packaging Market Share Insights

Blood Collection Tubes Account for Approximately 25% of Product-Type Demand

Blood collection tubes hold approximately 25% of the In Vitro Diagnostics Packaging Market in 2025, representing the largest product-type segment. Their position reflects the scale of routine hematology, chemistry, immunoassay, coagulation, infectious-disease and molecular testing. Tubes serve simultaneously as specimen containers and pre-analytical processing systems, with configurations incorporating clot activators, anticoagulants, gel separators, preservatives or other additives according to intended analysis.

Tube dimensions, draw volume, closure configuration and barcode position also interact with automated laboratory workflows. Collection-system design therefore influences the pathway from specimen acquisition through centrifugation, transport, sorting and analyzer loading rather than functioning solely as passive packaging.

Sample and transport tubes, reagent containers and microplates form other important product categories, while pouches, trays, cartons and labels support kit protection, organization and regulated product information.

Infectious Disease Diagnostics Hold Approximately 30% of Application Demand

Infectious disease diagnostics account for approximately 30% of market demand by application. Demand extends beyond pandemic testing to respiratory pathogens, HIV, hepatitis, sexually transmitted infections, gastrointestinal pathogens and other communicable diseases. Diagnostic formats include centralized molecular assays, antigen tests, lateral-flow kits, culture systems and specimen-transport products, resulting in demand across tubes, reagent containers, barrier pouches and diagnostic-kit packaging.

Packaging requirements vary substantially by technology. Molecular assays can use multiple reagent components and controls, whereas rapid tests commonly combine a disposable cassette or strip with buffer containers and specimen-collection components.

Cancer Diagnostics Represent Approximately 20% of Application Demand

Cancer diagnostics account for approximately 20% of market demand. Packaging demand spans pathology, molecular oncology, companion diagnostics, liquid-biopsy workflows and other tests requiring controlled specimen collection and reagent storage. Blood-based molecular testing increases the importance of sample-preservation tubes, while tissue and pathology applications create separate requirements for specimen containers, slides, reagents and transport systems.

Regulatory, Labeling and Quality Framework for IVD Packaging

IVD packaging is closely linked to labeling, stability and identification because the package can carry information needed to interpret storage conditions, expiration, lot identity and intended use. Regulatory treatment differs between professional laboratory reagents, self-testing products, specimen transport systems and medical-device identification frameworks.

FDA Requirements Apply to Immediate Containers, Outer Packaging and Package Inserts

Under 21 CFR 809.10, FDA's In Vitro Diagnostic Device Labeling Requirements specify information for IVD immediate containers and outer packaging. Relevant requirements include product identity, intended use, warnings, manufacturer information, lot or control number, storage instructions and, for reagents, information associated with stability and expiration.

FDA also specifies specimen-collection and preparation information in IVD labeling, including additives used to preserve specimen integrity and recommended storage, handling and shipping conditions. This creates a direct regulatory relationship between diagnostic packaging and pre-analytical performance.

ISO 18113 Addresses Labeling for Professional and Self-Test IVD Reagents

ISO 18113-2:2022 covers information supplied with IVD reagents, calibrators and controls intended for professional use and applies to immediate-container labels, outer-container labels and instructions for use.

ISO 18113-4:2022 provides corresponding requirements for IVD reagents intended for self-testing. Its inclusion of immediate containers, outer packaging and instructions is particularly relevant as diagnostic testing moves into home environments where package information forms part of the user's test workflow.

ISO 23640 Connects Reagent Packaging with Shelf Life and Transport Stability

ISO 23640:2011 on IVD reagent stability covers stability evaluation for reagents, calibrators, controls, diluents, buffers and reagent kits. It addresses shelf life, transport stability and stability after opening of the primary container and can also apply to specimen-collection devices containing preservatives or reaction-initiating substances.

The 2011 edition remains the published standard, while a second edition is under development as ISO/DIS 23640 in 2026. This framework provides a direct technical basis for evaluating reagent bottles, vials, closures and preservation-containing specimen tubes.

EU IVDR Transition Continues While EUDAMED Becomes Mandatory

The EU IVDR has applied since May 2022, but qualifying legacy devices remain subject to staggered transitional provisions rather than a single completed transition date. The European Commission's IVDR transitional provisions extend applicable transition periods through December 2027, 2028 or 2029, depending on device class and specified conditions.

A major 2026 change is the mandatory use of EUDAMED's Actor, UDI/Device, Notified Bodies & Certificates and Market Surveillance modules from May 28, 2026. The UDI/Device module connects device identification and registered information with regulated IVD labeling and packaging.

WHO Updates Infectious-Substance Transport Packaging Requirements

WHO's Guidance on Regulations for the Transport of Infectious Substances 2025–2026 applies from October 1, 2025 and covers classification, packaging, marking, labeling and documentation for infectious substances transported by different modes. It includes detailed treatment of applicable triple-packaging systems.

This framework is relevant to IVD specimen transport but should not be interpreted as applying identically to every commercial diagnostic kit. Transport packaging requirements depend on the classification and characteristics of the biological material being shipped.

Specimen Collection Packaging Evolves Around Sample Stability and Laboratory Automation

Specimen collection is the first packaging-intensive stage of many diagnostic workflows. Blood and urine tubes, collection cups and transport containers can determine the environment in which a biological sample remains before laboratory analysis.

Blood collection tubes use controlled draw volumes and additives selected according to the intended test. EDTA tubes support hematology and selected molecular applications; citrate systems are associated with coagulation testing; serum tubes can contain clot activators and separation gels; and other formulations preserve analytes for specific assays. The tube therefore functions simultaneously as a package, processing vessel and standardized interface with laboratory equipment.

Urine systems are undergoing similar functional development. BD's three-tube platform separates culture, routine urinalysis and additional testing from one collection event, while Greiner Bio-One's STB platform uses a preservation additive to maintain selected urine parameters for up to 72 hours at room temperature.

Laboratory automation adds another packaging dimension. Tube diameter, length, cap profile, barcode positioning and specimen volume affect automated sorting, decapping, centrifugation and analyzer loading. Greiner also offers pre-barcoded urine tubes, demonstrating the integration of physical container design with laboratory identification workflows.

Reagent and Diagnostic Device Packaging Advances Through Barrier and Active-Material Technologies

IVD reagents include liquids, buffers, controls, calibrators and dried chemistries with different sensitivities to oxygen, moisture, temperature and light. Their primary packaging can include plastic bottles, glass or polymer vials, foil pouches, blister-like structures and sealed cartridges.

Reagent bottles and vials must maintain product composition through shelf life and, where relevant, after first opening. Evaporation can alter reagent concentration, while oxygen or moisture ingress can affect sensitive chemistries. Closure performance, dispensing characteristics and headspace are consequently important elements of package performance.

Active-material technologies provide another route to control the microenvironment around diagnostic components. Aptar Active Material Science currently offers Activ-Film, Activ-Tab and Activ-Vial platforms for diagnostic products. The materials can adsorb moisture, scavenge oxygen or volatile compounds and are used in applications including lateral-flow tests, molecular diagnostics and blood-glucose test-strip containers.

High-barrier flexible packaging plays a complementary role. Diagnostic cassettes, sensors and moisture-sensitive components can be sealed in foil or polymer laminates with defined water-vapor and oxygen transmission characteristics. Amcor's 2025 high-shield laminates provide evidence of increasing material options within this segment.

Point-of-Care and At-Home Testing Changes Diagnostic Kit Packaging Architecture

Point-of-care and self-testing move diagnostic procedures away from trained centralized laboratory environments. Packaging therefore performs a stronger organizational and information function in addition to protecting the test components.

A home or point-of-care kit can contain a swab, lancet or collection device, specimen tube, buffer bottle or ampoule, pipette or dropper, test cartridge or cassette, absorbent materials and instructions. Packaging separates components while presenting them in a sequence consistent with the test procedure.

Moisture protection is particularly relevant to lateral-flow devices and other dry diagnostic chemistries. Foil pouches and active moisture-control materials can maintain the microenvironment around the cassette or strip before use. Aptar's Activ-Film, for example, can be attached to the diagnostic strip or pouch to adsorb moisture without functioning as a loose desiccant sachet.

Self-test packaging also carries a greater information burden. ISO 18113-4:2022 specifically addresses manufacturer-supplied information for self-testing IVD reagents, including both immediate and outer containers.

Specimen Transport and Temperature-Controlled Packaging Protect Samples Outside the Laboratory

Specimens frequently move between collection sites and centralized laboratories, making transport packaging part of the pre-analytical diagnostic chain. Packaging requirements depend on specimen type, infectious-risk classification, transport duration and required temperature conditions.

For infectious substances subject to transport regulations, triple packaging commonly combines a leakproof primary receptacle, protective secondary packaging and a rigid outer package. Absorbent material, cushioning, marking and documentation can also form part of the configuration according to the applicable classification. WHO's updated 2025–2026 guidance provides the current international technical framework.

Temperature control is product-specific. Some specimens and diagnostic reagents tolerate ambient conditions for defined periods, while others require refrigeration, freezing or other controlled environments. Greiner Bio-One's Urine STB tube illustrates how container chemistry can extend room-temperature specimen stability, reducing the relationship between preservation and refrigeration for that specific application.

Conversely, reagent kits, controls and molecular diagnostic components with narrower stability ranges can require cold-chain packaging systems, including insulated shippers, refrigerants and temperature-monitoring devices during distribution.

UDI, Barcoding and Labeling Expand Package-Level Identification and Traceability

Identification technologies in IVD packaging range from legally required labeling to operational laboratory barcodes and optional digital tracking technologies. These functions should not be treated as interchangeable.

In the United States, 21 CFR 809.10 requires lot or control numbers for IVD products and specifies information on immediate and outer containers. FDA's UDI framework adds device-identification requirements where applicable, but it does not require RFID or NFC as the identification technology.

The European IVDR similarly uses the UDI framework, with EUDAMED's UDI/Device registration module becoming mandatory from May 28, 2026.

Laboratory barcoding serves another function by linking the patient specimen to laboratory information systems and automated processing. Pre-barcoded tubes, machine-readable laboratory labels and consistent label placement reduce the gap between physical specimen packaging and digital laboratory records.

In Vitro Diagnostics Packaging Market Analysis by Country and Region

United States: IVD Labeling and Specimen-Collection Innovation Define Packaging Requirements

The U.S. market operates under FDA's dedicated IVD labeling requirements in 21 CFR 809.10, which apply to immediate containers, outer packaging and package inserts. Required information can include product identification, lot/control number, storage conditions and specimen-handling information.

Recent commercial activity is particularly visible in specimen collection. BD's February 2026 Urine Complete Cup Kit integrates a collection container and three separate tube configurations within a closed system and is designed for compatibility with laboratory automation.

The U.S. market also has established UDI infrastructure and substantial demand from clinical laboratories, hospital systems and decentralized testing. This provides a stronger packaging-specific market narrative than generic QR-code adoption or consumer sustainability preferences.

Germany and the European Union: IVDR Transition and Mandatory EUDAMED Use Strengthen Identification Requirements

Germany operates within the EU IVDR framework, but the regulatory transition did not end universally in May 2022. Regulation (EU) 2024/1860 extended transition periods for qualifying legacy IVDs through 2027–2029 depending on device class and other conditions.

The regulatory environment changed further on May 28, 2026, when the first four EUDAMED modules became mandatory, including UDI/Device registration. Packaging and labels consequently form part of a broader device-identification system rather than a generalized pharmaceutical-style serialization framework.

European packaging activity also includes growing interest in recyclable-oriented protective laminates. Amcor's high-shield medical laminates, including applications for diagnostic sensors, provide a current example while retaining distinct barrier tiers for different product requirements.

China: Risk-Based IVD Registration Provides the Core Regulatory Framework

China regulates IVD reagents as medical devices through the NMPA. The official registration and filing framework covers reagents, reagent kits, calibrators and control materials used for examination of human specimens and applies a risk-based regulatory structure.

This provides a more direct basis for IVD packaging analysis than broad references to Healthy China, artificial intelligence or national carbon targets. Packaging requirements are connected with the registered diagnostic product, reagent stability, labeling and controlled manufacture.

China's large domestic diagnostics and laboratory-consumables industry creates demand across reagent containers, collection tubes, microplates, kit packaging and protective materials. Localized production also supports high-volume infectious-disease, chronic-disease and molecular testing applications.

Japan: IVD Product Information and Precision Laboratory Packaging Support a Mature Diagnostics Base

Japan regulates IVDs through its pharmaceutical and medical-device framework, with the Pharmaceuticals and Medical Devices Agency providing product information, recalls and electronic package-insert access for in vitro diagnostics.

The packaging environment is characterized by reagent identification, controlled specimen handling and high-precision laboratory consumables rather than generic IoT-enabled packaging. Japan's established automation-intensive laboratory environment also places importance on dimensional consistency, machine-readable identification and compatibility between tubes, racks, plates and analytical systems.

Electronic package inserts add a digital information layer, but they remain distinct from physical package-integrity and reagent-stability functions.

Brazil: IVD Reclassification and UDI Implementation Update the Regulatory Environment

Brazil's IVD regulatory framework changed through RDC 830/2023, which revised risk classification and regularization requirements. In June 2025, Anvisa cancelled IVD notifications that had not completed the required reclassification process within the transition period.

UDI implementation has also advanced. Class IV medical devices manufactured from July 10, 2025 are required to carry UDI on their labels, and Brazil's SIUD device-identification database entered operation from March 1, 2026.

The combination of updated IVD classification and phased UDI implementation provides a stronger packaging-related regulatory narrative than generic local-manufacturing or AI claims.

United Kingdom: New Post-Market Surveillance Rules and IVD Roadmap Reshape the Regulatory Environment

Great Britain's updated medical-device post-market surveillance requirements became applicable to medical devices, including IVDs, placed on the market or put into service from June 16, 2025. The framework addresses incident reporting and preventive and corrective actions following market entry.

In December 2025, the MHRA also published an IVD Roadmap covering regulatory support, regulatory science, cancer diagnostics, companion diagnostics and pandemic preparedness through 2026–2027.

Competitive Landscape: Specimen Collection, Barrier Packaging and Diagnostic Containers Define Competition

The In Vitro Diagnostics Packaging Market includes specimen-collection companies, laboratory-consumables manufacturers, healthcare converters, primary-container specialists and active-material suppliers. Companies include Amcor plc, Gerresheimer AG, AptarGroup, Inc., SCHOTT AG, DWK Life Sciences LLC, Thermo Fisher Scientific Inc., Corning Incorporated, Greiner Bio-One GmbH, Tekni-Plex, Inc., Comar, LLC, Becton, Dickinson and Company, West Pharmaceutical Services, Inc., Placon Corporation, Sealed Air Corporation, and Nelipak Healthcare Packaging. Their activities span collection tubes, laboratory plastics, bottles and vials, active moisture-control materials, flexible barrier packaging, thermoformed trays, labels, secondary protective packaging and customized healthcare packaging.

Competition is differentiated by specimen compatibility, container cleanliness, dimensional consistency, reagent-barrier performance, cleanroom manufacturing, active-material technologies and regional converting capacity. BD and Greiner Bio-One have particularly strong exposure to specimen-collection systems; Aptar participates through active packaging materials for diagnostic tests; and Amcor, TekniPlex and Nelipak provide flexible and rigid healthcare packaging platforms. Nelipak expanded its regional footprint through its 2025 Costa Rica investment and acquisition of Merrill's Packaging. 

In Vitro Diagnostics Packaging Market Report Scope

In Vitro Diagnostics Packaging Market

Parameter	Details
Market Size (2025)	$10 Billion
Market Size (2034)	$15.2 Billion
Market Growth Rate	4.8%
Segments	By Product Type (Reagent & Solution Bottles, Blood Collection Tubes, Sample & Transport Tubes, Vials & Ampoules, Culture & Media Bottles, Microplates & Dishes, Pouches & Bags, Folding Cartons & Trays, Labels & Package Inserts), By Material (Plastic, Glass, Paper & Paperboard), By End-User (Hospitals, Clinical Laboratories, Academic & Research Institutes, Point-of-Care Testing Facilities), By Application (Infectious Disease Diagnostics, Cancer Diagnostics, Diabetes Diagnostics, Cardiology Diagnostics, Nephrology Diagnostics, Others)
Study Period	2020- 2025 and 2026-2034
Units	Revenue (USD)
Qualitative Analysis	Porter’s Five Forces, SWOT Profile, Market Share, Scenario Forecasts, Market Ecosystem, Company Ranking, Market Dynamics, Industry Benchmarking
Companies	Amcor plc, Gerresheimer AG, AptarGroup, Inc., SCHOTT AG, DWK Life Sciences LLC, Thermo Fisher Scientific Inc., Corning Incorporated, Greiner Bio-One GmbH, Tekni-Plex, Inc., Comar, LLC, Becton, Dickinson and Company, West Pharmaceutical Services, Inc., Placon Corporation, Sealed Air Corporation, Nelipak Healthcare Packaging
Countries	US, Canada, Mexico, Germany, France, Spain, Italy, UK, Russia, China, India, Japan, South Korea, Australia, South East Asia, Brazil, Argentina, Middle East, Africa

In Vitro Diagnostics Packaging Market Segmentation

By Product Type

• Reagent & Solution Bottles
• Blood Collection Tubes
• Sample & Transport Tubes
• Vials & Ampoules
• Culture & Media Bottles
• Microplates & Dishes
• Pouches & Bags
• Folding Cartons & Trays
• Labels & Package Inserts

By Material

• Plastic
• Glass
• Paper & Paperboard

By End-User

• Hospitals
• Clinical Laboratories
• Academic & Research Institutes
• Point-of-Care Testing Facilities

By Application

• Infectious Disease Diagnostics
• Cancer Diagnostics
• Diabetes Diagnostics
• Cardiology Diagnostics
• Nephrology Diagnostics
• Others

Countries Analyzed

• North America (US, Canada, Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
• South America (Brazil, Argentina, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Top Companies in In Vitro Diagnostics Packaging Market

• Amcor plc
• Gerresheimer AG
• AptarGroup, Inc.
• SCHOTT AG
• DWK Life Sciences LLC
• Thermo Fisher Scientific Inc.
• Corning Incorporated
• Greiner Bio-One GmbH
• Tekni-Plex, Inc.
• Comar, LLC
• Becton, Dickinson and Company
• West Pharmaceutical Services, Inc.
• Placon Corporation
• Sealed Air Corporation
• Nelipak Healthcare Packaging

* List Not Exhaustive

Methodology

USDAnalytics has prepared the In Vitro Diagnostics (IVD) Packaging Market analysis through a rigorous methodology combining primary interviews with packaging engineers, regulatory experts, laboratory managers, and supply chain professionals across key regions, alongside secondary research using company reports, regulatory filings, trade journals, and verified industry publications. Market sizing, CAGR, and trend forecasts were derived using a mix of top-down and bottom-up approaches, cross-validated through triangulation with historical shipment data, technology adoption rates, and materials cost indices. The methodology also incorporates regulatory frameworks such as IVDR, UDI/serialization, and national IVD classification catalogs, as well as technological innovations in high-barrier polymers, smart labels (RFID/NFC), and PCR-integrated recyclable packaging. USDAnalytics further analyzed competitive strategies, regional infrastructure, point-of-care adoption, and sustainability initiatives to provide actionable insights on product types, applications, end-users, and material trends, ensuring a robust, industry-focused outlook for decision-makers in IVD packaging.

Deliverables:

• Comprehensive Market Research Report (PDF and Excel) with detailed tables, charts, and interactive visualizations.
• Country-Specific Forecasts & Analysis.
• Segment-Wise Revenue Forecasts (2026–2034).
• Competitive Analysis, Benchmarking, and SWOT Profiles.
• Recent Developments & Innovation Tracker.
• Executive Summary & Analyst Commentary.
• Post-Purchase Analyst Support for Client-Specific Questions and Custom Data Requirements.

Table of Contents: In Vitro Diagnostics (IVD) Packaging Market
1. Executive Summary
1.1. Market Highlights
1.2. Key Findings
1.3. Global Market Snapshot
2. IVD Packaging Market Landscape & Outlook (2025–2034)
2.1. Introduction to IVD Packaging Market
2.2. Market Valuation and Growth Projections (2025–2034)
2.3. Key Market Drivers
2.4. Market Restraints and Challenges
2.5. Market Opportunities and Future Outlook
3. Innovations Reshaping the IVD Packaging Market
3.1. Trend: Adoption of High-Barrier Polymer Pouches to Replace Glass Vials
3.2. Trend: Integration of Smart and Connected Packaging for Chain of Custody
3.3. Opportunity: Development of Sustainable, PCR-Integrated Packaging
3.4. Opportunity: Packaging Designed for At-Home and Point-of-Care Diagnostic Collection Kits
4. Competitive Landscape and Strategic Initiatives
4.1. Mergers, Acquisitions and Strategic Alliances
4.2. R&D and Material Innovation
4.3. Sustainability and Strategies
4.4. Market Expansion and Regional Focus
5. Market Share and Segmentation Insights: IVD Packaging Market
5.1. By Product Type
5.1.1. Reagent & Solution Bottles
5.1.2. Blood Collection Tubes
5.1.3. Sample & Transport Tubes
5.1.4. Vials & Ampoules
5.1.5. Culture & Media Bottles
5.1.6. Microplates & Dishes
5.1.7. Pouches & Bags
5.1.8. Folding Cartons & Trays
5.1.9. Labels & Package Inserts
5.2. By Material
5.2.1. Plastic
5.2.2. Glass
5.2.3. Paper & Paperboard
5.3. By End-User
5.3.1. Hospitals
5.3.2. Clinical Laboratories
5.3.3. Academic & Research Institutes
5.3.4. Point-of-Care Testing Facilities
5.4. By Application
5.4.1. Infectious Disease Diagnostics
5.4.2. Cancer Diagnostics
5.4.3. Diabetes Diagnostics
5.4.4. Cardiology Diagnostics
5.4.5. Nephrology Diagnostics
5.4.6. Others
6. Country Analysis and Outlook of IVD Packaging Market
6.1. United States
6.2. Canada
6.3. Mexico
6.4. Germany
6.5. France
6.6. Spain
6.7. Italy
6.8. UK
6.9. Russia
6.10. China
6.11. India
6.12. Japan
6.13. South Korea
6.14. Australia
6.15. South East Asia
6.16. Brazil
6.17. Argentina
6.18. Middle East
6.19. Africa
7. IVD Packaging Market Size Outlook by Region (2025–2034)
7.1. North America IVD Packaging Market Size Outlook to 2034
7.1.1. By Product Type
7.1.2. By Material
7.1.3. By End-User
7.1.4. By Application
7.2. Europe IVD Packaging Market Size Outlook to 2034
7.2.1. By Product Type
7.2.2. By Material
7.2.3. By End-User
7.2.4. By Application
7.3. Asia Pacific IVD Packaging Market Size Outlook to 2034
7.3.1. By Product Type
7.3.2. By Material
7.3.3. By End-User
7.3.4. By Application
7.4. South America IVD Packaging Market Size Outlook to 2034
7.4.1. By Product Type
7.4.2. By Material
7.4.3. By End-User
7.4.4. By Application
7.5. Middle East and Africa IVD Packaging Market Size Outlook to 2034
7.5.1. By Product Type
7.5.2. By Material
7.5.3. By End-User
7.5.4. By Application
8. Company Profiles: Leading Players in the IVD Packaging Market
8.1. Amcor plc
8.2. Gerresheimer AG
8.3. AptarGroup, Inc.
8.4. SCHOTT AG
8.5. DWK Life Sciences LLC
8.6. Thermo Fisher Scientific Inc.
8.7. Corning Incorporated
8.8. Greiner Bio-One GmbH
8.9. Tekni-Plex, Inc.
8.10. Comar, LLC
8.11. Becton, Dickinson and Company
8.12. West Pharmaceutical Services, Inc.
8.13. Placon Corporation
8.14. Sealed Air Corporation
8.15. Nelipak Healthcare Packaging
9. Methodology
9.1. Research Scope
9.2. Market Research Approach
9.3. Market Sizing and Forecasting Model
9.4. Research Coverage
9.5. Data Horizon
9.6. Deliverables
10. Appendix
10.1. Acronyms and Abbreviations
10.2. List of Tables
10.3. List of Figures

In Vitro Diagnostics Packaging Market Segmentation

By Product Type

• Reagent & Solution Bottles
• Blood Collection Tubes
• Sample & Transport Tubes
• Vials & Ampoules
• Culture & Media Bottles
• Microplates & Dishes
• Pouches & Bags
• Folding Cartons & Trays
• Labels & Package Inserts

By Material

• Plastic
• Glass
• Paper & Paperboard

By End-User

• Hospitals
• Clinical Laboratories
• Academic & Research Institutes
• Point-of-Care Testing Facilities

By Application

• Infectious Disease Diagnostics
• Cancer Diagnostics
• Diabetes Diagnostics
• Cardiology Diagnostics
• Nephrology Diagnostics
• Others

Countries Analyzed

• North America (US, Canada, Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
• South America (Brazil, Argentina, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)